• Home
  • Search Results
  • Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience.

Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience.

European heart journal (2014-05-20)
Philippe Menasché, Valérie Vanneaux, Jean-Roch Fabreguettes, Alain Bel, Lucie Tosca, Sylvie Garcia, Valérie Bellamy, Yohan Farouz, Julia Pouly, Odile Damour, Marie-Cécile Périer, Michel Desnos, Albert Hagège, Onnik Agbulut, Patrick Bruneval, Gérard Tachdjian, Jean-Hugues Trouvin, Jérôme Larghero

There is now compelling evidence that cells committed to a cardiac lineage are most effective for improving the function of infarcted hearts. This has been confirmed by our pre-clinical studies entailing transplantation of human embryonic stem cell (hESC)-derived cardiac progenitors in rat and non-human primate models of myocardial infarction. These data have paved the way for a translational programme aimed at a phase I clinical trial. The main steps of this programme have included (i) the expansion of a clone of pluripotent hESC to generate a master cell bank under good manufacturing practice conditions (GMP); (ii) a growth factor-induced cardiac specification; (iii) the purification of committed cells by immunomagnetic sorting to yield a stage-specific embryonic antigen (SSEA)-1-positive cell population strongly expressing the early cardiac transcription factor Isl-1; (iv) the incorporation of these cells into a fibrin scaffold; (v) a safety assessment focused on the loss of teratoma-forming cells by in vitro (transcriptomics) and in vivo (cell injections in immunodeficient mice) measurements; (vi) an extensive cytogenetic and viral testing; and (vii) the characterization of the final cell product and its release criteria. The data collected throughout this process have led to approval by the French regulatory authorities for a first-in-man clinical trial of transplantation of these SSEA-1(+) progenitors in patients with severely impaired cardiac function. Although several facets of this manufacturing process still need to be improved, these data may yet provide a useful platform for the production of hESC-derived cardiac progenitor cells under safe and cost-effective GMP conditions.

Product Number
Product Description

Tyrosine, European Pharmacopoeia (EP) Reference Standard
DL-Tyrosine, 99%